Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542694 | 0.88 | TP53 (0.58) | NR1H4MAPTTP53POLB | |
| SCHEMBL2546275 | 0.87 | NR1H4 (0.65) | NR1H4MAPTTP53POLB | |
| SCHEMBL22299813 | 0.86 | MAPT (0.54) | NR1H4MAPTTP53POLB | |
| SCHEMBL16702269 | 0.80 | NR1H4 (0.85) | NR1H4MAPTTP53POLB | |
| SCHEMBL16709823 | 0.78 | NR1H4 (0.55) | NR1H4MAPTTP53POLB | |
| SCHEMBL21574277 | 0.76 | NR1H4 (0.51) | NR1H4MAPTPOLB | |
| SCHEMBL19810692 | 0.76 | TP53 (0.55) | NR1H4MAPTTP53POLB | |
| SCHEMBL16702360 | 0.76 | NR1H4 (0.53) | NR1H4MAPTPOLB | |
| SCHEMBL17978169 | 0.76 | TP53 (0.59) | NR1H4MAPTTP53POLB | |
| SCHEMBL16702182 | 0.75 | NR1H4 (0.62) | NR1H4MAPTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885TP53 4474/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | NR1H4 1/4885MAPT 4447/4885TP53 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.